RapamycinFungusV1, Main, Exploration, bibRecord, 000952

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Identifieur interne : 000952 ( Main/Exploration ); précédent : 000951; suivant : 000953

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Auteurs : David R. Driscoll [États-Unis] ; Saadia A. Karim [Royaume-Uni] ; Makoto Sano [Japon] ; David M. Gay [Royaume-Uni] ; Wright Jacob [Royaume-Uni] ; Jun Yu [États-Unis] ; Yusuke Mizukami [États-Unis] ; Aarthi Gopinathan [Royaume-Uni] ; Duncan I. Jodrell [Royaume-Uni] ; T R Jeffry Evans [Royaume-Uni] ; Nabeel Bardeesy [États-Unis] ; Michael N. Hall [Suisse] ; Brian J. Quattrochi [États-Unis] ; David S. Klimstra [États-Unis] ; Simon T. Barry [Royaume-Uni] ; Owen J. Sansom [Royaume-Uni] ; Brian C. Lewis [États-Unis] ; Jennifer P. Morton [Royaume-Uni]

Source :

Cancer research [ 1538-7445 ] ; 2016.

RBID : pubmed:27758884

Descripteurs français

KwdFr :
- Adénocarcinome (anatomopathologie), Adénocarcinome (génétique), Animaux (MeSH), Carcinome du canal pancréatique (anatomopathologie), Carcinome du canal pancréatique (génétique), Humains (MeSH), Lignée cellulaire tumorale (MeSH), Souris (MeSH), Sérine-thréonine kinases TOR (génétique), Transduction du signal (MeSH), Évolution de la maladie (MeSH).
MESH :
- anatomopathologie : Adénocarcinome, Carcinome du canal pancréatique.
- génétique : Adénocarcinome, Carcinome du canal pancréatique, Sérine-thréonine kinases TOR.
- Animaux, Humains, Lignée cellulaire tumorale, Souris, Transduction du signal, Évolution de la maladie.

English descriptors

KwdEn :
- Adenocarcinoma (genetics), Adenocarcinoma (pathology), Animals (MeSH), Carcinoma, Pancreatic Ductal (genetics), Carcinoma, Pancreatic Ductal (pathology), Cell Line, Tumor (MeSH), Disease Progression (MeSH), Humans (MeSH), Mice (MeSH), Signal Transduction (MeSH), TOR Serine-Threonine Kinases (genetics).
MESH :
- chemical , genetics : TOR Serine-Threonine Kinases.
- genetics : Adenocarcinoma, Carcinoma, Pancreatic Ductal.
- pathology : Adenocarcinoma, Carcinoma, Pancreatic Ductal.
- Animals, Cell Line, Tumor, Disease Progression, Humans, Mice, Signal Transduction.

Abstract

mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex. However, clinical trials of mTORC1 inhibitors in pancreatic cancer have failed, raising questions about this therapeutic approach. We employed a genetic approach to delete the obligate mTORC2 subunit Rictor and identified the critical times during which tumorigenesis requires mTORC2 signaling. Rictor deletion resulted in profoundly delayed tumorigenesis. Whereas previous studies showed most pancreatic tumors were insensitive to rapamycin, treatment with a dual mTORC1/2 inhibitor strongly suppressed tumorigenesis. In late-stage tumor-bearing mice, combined mTORC1/2 and PI3K inhibition significantly increased survival. Thus, targeting mTOR may be a potential therapeutic strategy in pancreatic cancer. Cancer Res; 76(23); 6911-23. ©2016 AACR.

DOI: 10.1158/0008-5472.CAN-16-0810
PubMed: 27758884
PubMed Central: PMC5135633

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000953
to stream Main, to step Curation: 000953

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.</title>
<author><name sortKey="Driscoll, David R" sort="Driscoll, David R" uniqKey="Driscoll D" first="David R" last="Driscoll">David R. Driscoll</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Karim, Saadia A" sort="Karim, Saadia A" uniqKey="Karim S" first="Saadia A" last="Karim">Saadia A. Karim</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sano, Makoto" sort="Sano, Makoto" uniqKey="Sano M" first="Makoto" last="Sano">Makoto Sano</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gay, David M" sort="Gay, David M" uniqKey="Gay D" first="David M" last="Gay">David M. Gay</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jacob, Wright" sort="Jacob, Wright" uniqKey="Jacob W" first="Wright" last="Jacob">Wright Jacob</name>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Jun" sort="Yu, Jun" uniqKey="Yu J" first="Jun" last="Yu">Jun Yu</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mizukami, Yusuke" sort="Mizukami, Yusuke" uniqKey="Mizukami Y" first="Yusuke" last="Mizukami">Yusuke Mizukami</name>
<affiliation wicri:level="2"><nlm:affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Cancer Center, Massachusetts General Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gopinathan, Aarthi" sort="Gopinathan, Aarthi" uniqKey="Gopinathan A" first="Aarthi" last="Gopinathan">Aarthi Gopinathan</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Cambridge Institute, Cambridge, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Cambridge Institute, Cambridge</wicri:regionArea>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jodrell, Duncan I" sort="Jodrell, Duncan I" uniqKey="Jodrell D" first="Duncan I" last="Jodrell">Duncan I. Jodrell</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Cambridge Institute, Cambridge, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Cambridge Institute, Cambridge</wicri:regionArea>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Evans, T R Jeffry" sort="Evans, T R Jeffry" uniqKey="Evans T" first="T R Jeffry" last="Evans">T R Jeffry Evans</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bardeesy, Nabeel" sort="Bardeesy, Nabeel" uniqKey="Bardeesy N" first="Nabeel" last="Bardeesy">Nabeel Bardeesy</name>
<affiliation wicri:level="2"><nlm:affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Cancer Center, Massachusetts General Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hall, Michael N" sort="Hall, Michael N" uniqKey="Hall M" first="Michael N" last="Hall">Michael N. Hall</name>
<affiliation wicri:level="1"><nlm:affiliation>Biozentrum, University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Biozentrum, University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Quattrochi, Brian J" sort="Quattrochi, Brian J" uniqKey="Quattrochi B" first="Brian J" last="Quattrochi">Brian J. Quattrochi</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Klimstra, David S" sort="Klimstra, David S" uniqKey="Klimstra D" first="David S" last="Klimstra">David S. Klimstra</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Barry, Simon T" sort="Barry, Simon T" uniqKey="Barry S" first="Simon T" last="Barry">Simon T. Barry</name>
<affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Macclesfield, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>AstraZeneca, Macclesfield</wicri:regionArea>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sansom, Owen J" sort="Sansom, Owen J" uniqKey="Sansom O" first="Owen J" last="Sansom">Owen J. Sansom</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom. o.sansom@beatson.gla.ac.uk Brian.Lewis@umassmed.edu.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lewis, Brian C" sort="Lewis, Brian C" uniqKey="Lewis B" first="Brian C" last="Lewis">Brian C. Lewis</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts. o.sansom@beatson.gla.ac.uk Brian.Lewis@umassmed.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Cancer Center, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morton, Jennifer P" sort="Morton, Jennifer P" uniqKey="Morton J" first="Jennifer P" last="Morton">Jennifer P. Morton</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27758884</idno>
<idno type="pmid">27758884</idno>
<idno type="doi">10.1158/0008-5472.CAN-16-0810</idno>
<idno type="pmc">PMC5135633</idno>
<idno type="wicri:Area/Main/Corpus">000953</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000953</idno>
<idno type="wicri:Area/Main/Curation">000953</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000953</idno>
<idno type="wicri:Area/Main/Exploration">000953</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.</title>
<author><name sortKey="Driscoll, David R" sort="Driscoll, David R" uniqKey="Driscoll D" first="David R" last="Driscoll">David R. Driscoll</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Karim, Saadia A" sort="Karim, Saadia A" uniqKey="Karim S" first="Saadia A" last="Karim">Saadia A. Karim</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sano, Makoto" sort="Sano, Makoto" uniqKey="Sano M" first="Makoto" last="Sano">Makoto Sano</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gay, David M" sort="Gay, David M" uniqKey="Gay D" first="David M" last="Gay">David M. Gay</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jacob, Wright" sort="Jacob, Wright" uniqKey="Jacob W" first="Wright" last="Jacob">Wright Jacob</name>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Jun" sort="Yu, Jun" uniqKey="Yu J" first="Jun" last="Yu">Jun Yu</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mizukami, Yusuke" sort="Mizukami, Yusuke" uniqKey="Mizukami Y" first="Yusuke" last="Mizukami">Yusuke Mizukami</name>
<affiliation wicri:level="2"><nlm:affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Cancer Center, Massachusetts General Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gopinathan, Aarthi" sort="Gopinathan, Aarthi" uniqKey="Gopinathan A" first="Aarthi" last="Gopinathan">Aarthi Gopinathan</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Cambridge Institute, Cambridge, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Cambridge Institute, Cambridge</wicri:regionArea>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jodrell, Duncan I" sort="Jodrell, Duncan I" uniqKey="Jodrell D" first="Duncan I" last="Jodrell">Duncan I. Jodrell</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Cambridge Institute, Cambridge, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Cambridge Institute, Cambridge</wicri:regionArea>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Evans, T R Jeffry" sort="Evans, T R Jeffry" uniqKey="Evans T" first="T R Jeffry" last="Evans">T R Jeffry Evans</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bardeesy, Nabeel" sort="Bardeesy, Nabeel" uniqKey="Bardeesy N" first="Nabeel" last="Bardeesy">Nabeel Bardeesy</name>
<affiliation wicri:level="2"><nlm:affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Cancer Center, Massachusetts General Hospital, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hall, Michael N" sort="Hall, Michael N" uniqKey="Hall M" first="Michael N" last="Hall">Michael N. Hall</name>
<affiliation wicri:level="1"><nlm:affiliation>Biozentrum, University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Biozentrum, University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Quattrochi, Brian J" sort="Quattrochi, Brian J" uniqKey="Quattrochi B" first="Brian J" last="Quattrochi">Brian J. Quattrochi</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Klimstra, David S" sort="Klimstra, David S" uniqKey="Klimstra D" first="David S" last="Klimstra">David S. Klimstra</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Barry, Simon T" sort="Barry, Simon T" uniqKey="Barry S" first="Simon T" last="Barry">Simon T. Barry</name>
<affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Macclesfield, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>AstraZeneca, Macclesfield</wicri:regionArea>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sansom, Owen J" sort="Sansom, Owen J" uniqKey="Sansom O" first="Owen J" last="Sansom">Owen J. Sansom</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom. o.sansom@beatson.gla.ac.uk Brian.Lewis@umassmed.edu.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lewis, Brian C" sort="Lewis, Brian C" uniqKey="Lewis B" first="Brian C" last="Lewis">Brian C. Lewis</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts. o.sansom@beatson.gla.ac.uk Brian.Lewis@umassmed.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Cancer Center, University of Massachusetts Medical School, Worcester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morton, Jennifer P" sort="Morton, Jennifer P" uniqKey="Morton J" first="Jennifer P" last="Morton">Jennifer P. Morton</name>
<affiliation wicri:level="1"><nlm:affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRUK Beatson Institute, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Cancer Sciences, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Cancer research</title>
<idno type="eISSN">1538-7445</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (genetics)</term>
<term>Adenocarcinoma (pathology)</term>
<term>Animals (MeSH)</term>
<term>Carcinoma, Pancreatic Ductal (genetics)</term>
<term>Carcinoma, Pancreatic Ductal (pathology)</term>
<term>Cell Line, Tumor (MeSH)</term>
<term>Disease Progression (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Signal Transduction (MeSH)</term>
<term>TOR Serine-Threonine Kinases (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adénocarcinome (anatomopathologie)</term>
<term>Adénocarcinome (génétique)</term>
<term>Animaux (MeSH)</term>
<term>Carcinome du canal pancréatique (anatomopathologie)</term>
<term>Carcinome du canal pancréatique (génétique)</term>
<term>Humains (MeSH)</term>
<term>Lignée cellulaire tumorale (MeSH)</term>
<term>Souris (MeSH)</term>
<term>Sérine-thréonine kinases TOR (génétique)</term>
<term>Transduction du signal (MeSH)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome du canal pancréatique</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Pancreatic Ductal</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome du canal pancréatique</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Pancreatic Ductal</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Mice</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Souris</term>
<term>Transduction du signal</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex. However, clinical trials of mTORC1 inhibitors in pancreatic cancer have failed, raising questions about this therapeutic approach. We employed a genetic approach to delete the obligate mTORC2 subunit Rictor and identified the critical times during which tumorigenesis requires mTORC2 signaling. Rictor deletion resulted in profoundly delayed tumorigenesis. Whereas previous studies showed most pancreatic tumors were insensitive to rapamycin, treatment with a dual mTORC1/2 inhibitor strongly suppressed tumorigenesis. In late-stage tumor-bearing mice, combined mTORC1/2 and PI3K inhibition significantly increased survival. Thus, targeting mTOR may be a potential therapeutic strategy in pancreatic cancer. Cancer Res; 76(23); 6911-23. ©2016 AACR.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27758884</PMID>
<DateCompleted><Year>2017</Year>
<Month>09</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7445</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>76</Volume>
<Issue>23</Issue>
<PubDate><Year>2016</Year>
<Month>12</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Cancer research</Title>
<ISOAbbreviation>Cancer Res</ISOAbbreviation>
</Journal>
<ArticleTitle>mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.</ArticleTitle>
<Pagination><MedlinePgn>6911-6923</MedlinePgn>
</Pagination>
<Abstract><AbstractText>mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex. However, clinical trials of mTORC1 inhibitors in pancreatic cancer have failed, raising questions about this therapeutic approach. We employed a genetic approach to delete the obligate mTORC2 subunit Rictor and identified the critical times during which tumorigenesis requires mTORC2 signaling. Rictor deletion resulted in profoundly delayed tumorigenesis. Whereas previous studies showed most pancreatic tumors were insensitive to rapamycin, treatment with a dual mTORC1/2 inhibitor strongly suppressed tumorigenesis. In late-stage tumor-bearing mice, combined mTORC1/2 and PI3K inhibition significantly increased survival. Thus, targeting mTOR may be a potential therapeutic strategy in pancreatic cancer. Cancer Res; 76(23); 6911-23. ©2016 AACR.</AbstractText>
<CopyrightInformation>©2016 American Association for Cancer Research.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Driscoll</LastName>
<ForeName>David R</ForeName>
<Initials>DR</Initials>
<AffiliationInfo><Affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Karim</LastName>
<ForeName>Saadia A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sano</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gay</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jacob</LastName>
<ForeName>Wright</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mizukami</LastName>
<ForeName>Yusuke</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gopinathan</LastName>
<ForeName>Aarthi</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>CRUK Cambridge Institute, Cambridge, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jodrell</LastName>
<ForeName>Duncan I</ForeName>
<Initials>DI</Initials>
<AffiliationInfo><Affiliation>CRUK Cambridge Institute, Cambridge, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Evans</LastName>
<ForeName>T R Jeffry</ForeName>
<Initials>TR</Initials>
<AffiliationInfo><Affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bardeesy</LastName>
<ForeName>Nabeel</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hall</LastName>
<ForeName>Michael N</ForeName>
<Initials>MN</Initials>
<AffiliationInfo><Affiliation>Biozentrum, University of Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Quattrochi</LastName>
<ForeName>Brian J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo><Affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Klimstra</LastName>
<ForeName>David S</ForeName>
<Initials>DS</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barry</LastName>
<ForeName>Simon T</ForeName>
<Initials>ST</Initials>
<AffiliationInfo><Affiliation>AstraZeneca, Macclesfield, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sansom</LastName>
<ForeName>Owen J</ForeName>
<Initials>OJ</Initials>
<AffiliationInfo><Affiliation>CRUK Beatson Institute, Glasgow, United Kingdom. o.sansom@beatson.gla.ac.uk Brian.Lewis@umassmed.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lewis</LastName>
<ForeName>Brian C</ForeName>
<Initials>BC</Initials>
<AffiliationInfo><Affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts. o.sansom@beatson.gla.ac.uk Brian.Lewis@umassmed.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morton</LastName>
<ForeName>Jennifer P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>CRUK Beatson Institute, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 CA155784</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>12946</GrantID>
<Acronym>CRUK_</Acronym>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>11650</GrantID>
<Acronym>CRUK_</Acronym>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>C596/A17196</GrantID>
<Acronym>CRUK_</Acronym>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>311301</GrantID>
<Acronym>ERC_</Acronym>
<Agency>European Research Council</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>C596/A18076</GrantID>
<Acronym>CRUK_</Acronym>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>A11650</GrantID>
<Acronym>CRUK_</Acronym>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>A12481</GrantID>
<Acronym>CRUK_</Acronym>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>F30 CA168063</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>A18076</GrantID>
<Acronym>CRUK_</Acronym>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>10</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Cancer Res</MedlineTA>
<NlmUniqueID>2984705R</NlmUniqueID>
<ISSNLinking>0008-5472</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>The authors have no competing interests to disclose</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>03</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>08</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>09</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>9</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27758884</ArticleId>
<ArticleId IdType="pii">0008-5472.CAN-16-0810</ArticleId>
<ArticleId IdType="doi">10.1158/0008-5472.CAN-16-0810</ArticleId>
<ArticleId IdType="pmc">PMC5135633</ArticleId>
<ArticleId IdType="mid">NIHMS827036</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Genes Dev. 2003 Dec 15;17(24):3112-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2012 May 11;149(4):780-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22579283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Discov. 2015 Nov;5(11):1194-209</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26293922</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acid Ther. 2014 Jun;24(3):210-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24552182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gut. 2014 Sep;63(9):1481-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24717934</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2004 Jul;127(1):250-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15236190</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2015 Jul 16;162(2):259-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26144316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2015 Jan 12;27(1):41-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25584893</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2011 Apr 12;19(4):456-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21481788</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochim Biophys Acta. 2014 Dec;1846(2):638-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25450580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Metab. 2008 Nov;8(5):411-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19046572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2014 Dec;147(6):1405-16.e7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25311989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2014 Jun 1;74(11):2913-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24840647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2012 Apr;122(4):1262-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22426206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2009 Jul 7;16(1):21-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19573809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cell Dev Biol. 2014 Dec;36:79-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25242279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2012 Feb 10;418(2):426-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22285861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem J. 2008 Dec 15;416(3):375-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18925875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Genet. 2002 Sep;32(1):128-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12185368</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2012 Nov 15;491(7424):399-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23103869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Cell Biol. 2004 Nov;6(11):1122-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15467718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2011 Apr 8;42(1):36-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21474066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gut. 2015 Sep;64(9):1476-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25994217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Nov 27;371(22):2140-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25427123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Oct 07;6:8501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26442967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2008 Dec 19;283(51):35375-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18952604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2003 Dec;4(6):437-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14706336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Signal. 2009 Apr 21;2(67):pe24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19383975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2473-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25675507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2014 Jul 24;511(7510):483-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25043018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Carcinogenesis. 2015 Jul;36(7):730-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25939753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2012 Feb;122(2):639-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22232209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncotarget. 2015 Sep 29;6(29):28120-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26356562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dev Cell. 2006 Dec;11(6):859-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17141160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Discov. 2015 Dec;5(12):1262-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26370156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2012 Apr 27;149(3):656-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22541435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2011 Jul 15;71(14):5020-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21586612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2008 Sep;118(9):3065-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18725988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2009 Feb 3;15(2):148-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19185849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25559415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2013 Jun;144(6):1180-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23622127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Investig Drugs. 2013 Jun;22(6):715-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23544840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2005 May;7(5):469-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15894267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2006 Mar;6(3):184-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16453012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2013 Mar;10(3):143-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23400000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Future Med Chem. 2011 Oct;3(14):1787-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22004085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2006 Feb 1;66(3):1500-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16452206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2015 Jun;12(6):319-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25824606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2013 Jul 15;19(14 ):3808-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23640975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2013 Mar 18;23 (3):406-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23453624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2015 Jan;14(1):48-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25398829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Biol. 2004 Jul 27;14(14):1296-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15268862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2011 Aug;141(2):719-30, 730.e1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21684285</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dev Cell. 2006 Oct;11(4):583-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16962829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2015 Aug 1;21(15):3412-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25805799</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
<li>Région de Kantō</li>
<li>Écosse</li>
<li>État de New York</li>
</region>
<settlement><li>Glasgow</li>
<li>Tokyo</li>
</settlement>
<orgName><li>Université de Glasgow</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Driscoll, David R" sort="Driscoll, David R" uniqKey="Driscoll D" first="David R" last="Driscoll">David R. Driscoll</name>
</region>
<name sortKey="Bardeesy, Nabeel" sort="Bardeesy, Nabeel" uniqKey="Bardeesy N" first="Nabeel" last="Bardeesy">Nabeel Bardeesy</name>
<name sortKey="Klimstra, David S" sort="Klimstra, David S" uniqKey="Klimstra D" first="David S" last="Klimstra">David S. Klimstra</name>
<name sortKey="Lewis, Brian C" sort="Lewis, Brian C" uniqKey="Lewis B" first="Brian C" last="Lewis">Brian C. Lewis</name>
<name sortKey="Lewis, Brian C" sort="Lewis, Brian C" uniqKey="Lewis B" first="Brian C" last="Lewis">Brian C. Lewis</name>
<name sortKey="Mizukami, Yusuke" sort="Mizukami, Yusuke" uniqKey="Mizukami Y" first="Yusuke" last="Mizukami">Yusuke Mizukami</name>
<name sortKey="Quattrochi, Brian J" sort="Quattrochi, Brian J" uniqKey="Quattrochi B" first="Brian J" last="Quattrochi">Brian J. Quattrochi</name>
<name sortKey="Yu, Jun" sort="Yu, Jun" uniqKey="Yu J" first="Jun" last="Yu">Jun Yu</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Karim, Saadia A" sort="Karim, Saadia A" uniqKey="Karim S" first="Saadia A" last="Karim">Saadia A. Karim</name>
</noRegion>
<name sortKey="Barry, Simon T" sort="Barry, Simon T" uniqKey="Barry S" first="Simon T" last="Barry">Simon T. Barry</name>
<name sortKey="Evans, T R Jeffry" sort="Evans, T R Jeffry" uniqKey="Evans T" first="T R Jeffry" last="Evans">T R Jeffry Evans</name>
<name sortKey="Evans, T R Jeffry" sort="Evans, T R Jeffry" uniqKey="Evans T" first="T R Jeffry" last="Evans">T R Jeffry Evans</name>
<name sortKey="Gay, David M" sort="Gay, David M" uniqKey="Gay D" first="David M" last="Gay">David M. Gay</name>
<name sortKey="Gopinathan, Aarthi" sort="Gopinathan, Aarthi" uniqKey="Gopinathan A" first="Aarthi" last="Gopinathan">Aarthi Gopinathan</name>
<name sortKey="Jacob, Wright" sort="Jacob, Wright" uniqKey="Jacob W" first="Wright" last="Jacob">Wright Jacob</name>
<name sortKey="Jodrell, Duncan I" sort="Jodrell, Duncan I" uniqKey="Jodrell D" first="Duncan I" last="Jodrell">Duncan I. Jodrell</name>
<name sortKey="Morton, Jennifer P" sort="Morton, Jennifer P" uniqKey="Morton J" first="Jennifer P" last="Morton">Jennifer P. Morton</name>
<name sortKey="Morton, Jennifer P" sort="Morton, Jennifer P" uniqKey="Morton J" first="Jennifer P" last="Morton">Jennifer P. Morton</name>
<name sortKey="Sansom, Owen J" sort="Sansom, Owen J" uniqKey="Sansom O" first="Owen J" last="Sansom">Owen J. Sansom</name>
<name sortKey="Sansom, Owen J" sort="Sansom, Owen J" uniqKey="Sansom O" first="Owen J" last="Sansom">Owen J. Sansom</name>
</country>
<country name="Japon"><region name="Région de Kantō"><name sortKey="Sano, Makoto" sort="Sano, Makoto" uniqKey="Sano M" first="Makoto" last="Sano">Makoto Sano</name>
</region>
</country>
<country name="Suisse"><noRegion><name sortKey="Hall, Michael N" sort="Hall, Michael N" uniqKey="Hall M" first="Michael N" last="Hall">Michael N. Hall</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000952 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000952 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27758884
   |texte=   mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27758884" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki